Sapalidis Konstantinos, Kosmidis Christoforos, Funtanidou Varvara, Katsaounis Athanasios, Barmpas Amastasios, Koimtzis Georgios, Mantalobas Stylianos, Alexandrou Vyron, Aidoni Zoi, Koulouris Charilaos, Pavlidis Efstathios, Giannakidis Dimitrios, Surlin Valeriu, Pantea Stelian, Strambu Victor, Constantina Rogoveanu Otilia, Amaniti Aikaterini, Zarogoulidis Paul, Mogoantă Stelian, Kesisoglou Isaak, Sardeli Chrysanthi
3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
Anesthesiology Department, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
J Cancer. 2019 Aug 28;10(21):5162-5172. doi: 10.7150/jca.36300. eCollection 2019.
Pancreatic cancer is still diagnosed at a late stage although we have novel diagnostic tools. Pancreatic cancer chemotherapy treatment resistance is observed and therefore novel treatments are in need. Anti-cancer stem cell therapy, combination of chemotherapy and/or radiotherapy with immunotherapy, proteins/enzymes and gene therapy are currently under evaluation. Targeted treatment with tyrosine kinase inhibitors is also administered and novel inhibitors are also under evaluation. In the current review we present recent data from our search within the year 2018.
尽管我们拥有新型诊断工具,但胰腺癌仍在晚期才被诊断出来。人们观察到胰腺癌化疗存在治疗抗性,因此需要新型治疗方法。抗癌干细胞疗法、化疗和/或放疗与免疫疗法的联合、蛋白质/酶和基因疗法目前正在评估中。酪氨酸激酶抑制剂的靶向治疗也在进行,新型抑制剂也在评估中。在本综述中,我们展示了2018年检索到的最新数据。